Neuclone Is A Clinical Stage Biopharmaceutical Company Based In Sydneyaustraliafounded In 2007The Company Specializes In Developing And Commercializing Biosimilar Monoclonal Antibody Therapiesaiming To Enhance Patient Access To Essential Biologic Treatments Through Affordable And High Quality Options That Are Clinically Identical To Original Products Neuclone Operates In The Early Development Stages Of Biosimilarsfocusing On Analytical Characterizationupstream Developmentand Preclinical And Clinical Trialsthe Company Has A Portfolio Of 10 Biosimilar Monoclonal Antibodies Targeting Various Diseasesincluding Cancer And Autoimmune Disordersneuclone Utilizes A Proprietary Cell Expression System To Optimize Biologic Production And Has Established A Global Partnership With Serum Institute Of India For Large Scale Manufacturing And Distributionsignificantly Reducing Costs The Company S Mission Is To Expand Access To Life Saving Therapies By Developing A Diverse Range Of Clinically Identical Biosimilars For Global Marketsneuclone Prioritizes Price Competitiveness And Quality Scienceensuring That Patient Needs Are At The Forefront Of Its Operations
No conferences found for this company.
| Company Name | Neuclone Proprietary Ltd |
| Country |
--
|
| Address | N/A |
| Telephone | N/A |
| N/A |
